Janux Therapeutics upgraded to Strong Buy with strong cash and promising partnerships worth $1.8B milestones.

Janux Therapeutics, a clinical-stage biopharmaceutical company, has been upgraded to Strong Buy due to its solid cash position and validated technology platforms. The company discontinued its JANX008 program to focus resources on higher-potential assets, demonstrating financial discipline. Strategic partnerships with Merck and Bristol-Myers Squibb could bring up to $1.8 billion in milestone payments plus royalties, supporting long-term value creation. Despite risks from its early-stage pipeline and potential near-term volatility, Janux's cash runway and platform progress make it a high-risk, long-term investment opportunity.